The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes
Abstract
BACKGROUND: Results from clinical trials examining the effect of intensive glucose control on cardiovascular disease have been conflicting. PURPOSE: To summarize clinical benefits and harms of intensive versus conventional glucose control for adults with type 2 diabetes. DATA SOURCES: Studies were retrieved by systematically searching the MEDLINE database (January 1950 to April 2009) with no language restrictions. STUDY SELECTION: Two independent reviewers screened abstracts or full-text articles to identify randomized trials that compared clinical outcomes in patients with type 2 diabetes receiving intensive glucose control and those receiving conventional glucose control. DATA EXTRACTION: Two investigators independently abstracted data on study variables and outcomes, including severe hypoglycemia, cardiovascular disease, and all-cause mortality. DATA SYNTHESIS: 5 trials involving 27,802 adults were included. Intensive glucose targets were lower in the 3 most recent trials. Summary analyses showed that compared with conventional control, intensive glucose control reduced the risk for cardiovascular disease (relative risk [RR], 0.90 [95% CI, 0.83 to 0.98]; risk difference per 1000 patients per 5 years [RD], -15 [CI, -24 to -5]) but not cardiovascular death (RR, 0.97 [CI, 0.76 to 1.24]; RD, -3 [CI, -14 to 7]) or all-cause mortality (RR, 0.98 [CI, 0.84 to 1.15]; RD, -4 [CI, -17 to 10]). Intensive glucose control increased the risk for severe hypoglycemia (RR, 2.03 [CI, 1.46 to 2.81]; RD, 39 [CI, 7 to 71]). As was seen in the overall analyses, pooled findings from the early and more recent trials showed that intensive glucose control reduced the risk for cardiovascular disease and increased the risk for severe hypoglycemia. LIMITATION: Summary rather than individual data were pooled across trials. CONCLUSION: Intensive glucose control reduced the risk for some cardiovascular disease outcomes (such as nonfatal myocardial infarction), did not reduce the risk for cardiovascular death or all-cause mortality, and increased the risk for severe hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A similar result was also found in another systematic review of the same data.450”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [450]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H. O. M., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,294
Research works printed but not linked: 2
- Shichiri M, 2000, Diabetes Care, 23, B21
- 10.1001/archinte.1997.00440230053007 · DOI
Cited by
Sorted by citations
Items 201–300 of 358
Kotseva, K. (2015) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-015-0415-9 · Cited by 10
Wan, E. Y. F., Yu, E. Y. T., Chen, J. Y., Wong, I. C. K., Chan, E. W., & Lam, C. L. K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14157 · Cited by 11
“This was also consistent with a systematic review which suggested that intensive HbA1c control significantly reduced CHD incidence in particular.(11) Another study led to similar findings, showing that an HbA1c level of 4.”
ResultFuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J. F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M., et al. (2021) · Neurología · doi:10.1016/j.nrl.2020.04.030 · Cited by 9
Koufakis, T., Liberopoulos, E. N., Kokkinos, A. D., Zebekakis, P. E., & Kotsa, K. (2023) · Drugs · doi:10.1007/s40265-023-01852-1 · Cited by 9
“However, a meta-analysis of the results of iconic T2D trials (UKPDS 33, UKPDS, ACCORD, ADVANCE, and VADT) showed that intensive glucose control reduced the risk of CVD, but not CV death or all-cause mortality, while at the same time increasing the risk of severe hypoglycemia [30].”
ResultAddressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care
STOLAR, M. W. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ec04e9 · Cited by 8
van der Leeuw, J., Visseren, F. L. J., Woodward, M., van der Graaf, Y., Grobbee, D. E., Harrap, S. B., Heller, S. R., Mancia, G., Marre, M., Poulter, N. R., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4082-5 · Cited by 8
“However, intensive glucose control is also associated with disadvantages, such as an approximately doubled risk of severe hypoglycaemia depending on the glucose-lowering treatment being received [6, 10].”
Concerns About Meta-analysis of Glucose Control and Cardiovascular Disease in Type 2 Diabetes
Yudkin, J. S., & Richter, B. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-1-201001050-00017 · Cited by 8
Transient ischemic attack: Part II. Risk factor modification and treatment.
Simmons, B. B., Gadegbeku, A. B., & Cirignano, B. (2012) · PubMed · Cited by 8
Correlates of low hemoglobin A1c in maintenance hemodialysis patients
Kim, Y., Park, J. C., Molnar, M. Z., Shah, A. P., Benner, D., Kovesdy, C. P., Kopple, J. D., & Kalantar‐Zadeh, K. (2012) · International Urology and Nephrology · doi:10.1007/s11255-012-0208-y · Cited by 8
Do we need new treatments for type 2 diabetes?
Peralta, F. G., & Padín, C. A. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2014.06.002 · Cited by 8
Diabetes mellitus tipo 2: nuevos tratamientos
Ascaso, J. F. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.05.041 · Cited by 10
Cardiovascular Importance of Hyperglycemia and Hypoglycemia
Tkáč, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2044 · Cited by 8
La prevención cardiovascular en la diabetes mellitus: un reto multifactorial
Pedro‐Botet, J., Chillarón, J. J., Benaiges, D., & Roux, J. A. F. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.10.003 · Cited by 9
Postoperative Complications after Thoracic Surgery in the Morbidly Obese Patient
Cooper, L. (2011) · Anesthesiology Research and Practice · doi:10.1155/2011/865634 · Cited by 8
“The risks increased in older patients, coexisting severe comorbidities, the presence of undiagnosed hypoglycemia, and the duration of diabetes and insulin therapy [37, 38].”
BackgroundDifferent intensities of glycaemic control for pregnant women with pre-existing diabetes
Middleton, P., Crowther, C. A., Simmonds, L., & Müller, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008540.pub2 · Cited by 9
Glycated hemoglobin A1c(HbA1c) and diabetes: a new era?
Katsiki, N., Παπάνας, Ν., Mikhailidis, D. P., & Fonseca, V. A. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.618179 · Cited by 8
Self-citationDose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure
Sharma, D., Asirvatham, A. J., & Singh, P. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_16 · Cited by 7
Hemoglobin A1c as a Diagnostic Tool: Public Health Implications From an Actor–Network Perspective
Degeling, C., & Rock, M. J. (2011) · American Journal of Public Health · doi:10.2105/ajph.2011.300329 · Cited by 8
“In follow-up studies, aggressive glucose-specific measures have been found to be inadequate for achieving the stated goals of reducing the incidence of macrovascular fatalities in people diagnosed with type 2 diabetes.(31,32) Although these results are contested, the weight of opinion is that disciplined glucose regul…”
BackgroundThomopoulos, C., Bazoukis, G., Ilias, Ι., Tsioufis, C. P., & Makris, T. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002152 · Cited by 7
Kumsar, Ş., Sağlam, H. S., Köse, O., Budak, S., & Adsan, Ö. (2014) · Urology Annals · doi:10.4103/0974-7796.140995 · Cited by 7
“HbA1c is a highly reliable measure of long‐term glycemic control often used to follow ongoing adjustments to medications in patients with diabetes mellitus.[21] More recently in the surgical data, HbA1c has been demonstrated to be a preoperative predictor of postoperative outcomes.”
Sone, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99593-0 · Cited by 7
Licorice Extract Isoliquiritigenin Protects Endothelial Function in Type 2 Diabetic Mice
Wang, L., Zhu, R., He, C., Li, H., Zhang, Q., Cheung, Y. M., Leung, F. P., & Wong, W. T. (2024) · Nutrients · doi:10.3390/nu16183160 · Cited by 7
“…(mouse, syringe, aorta, arteries, and cytokines) shown in the Graphical Abstract and Figure 1A were used from or adapted from pictures provided by Servier Medical Art (Servier; https://smart.servier.com/, accessed on 28 June 2024), licensed under a Creative Commons Attribution 4.0 Unported License.”
BackgroundMethodInfluentialGlucose Control and Cardiovascular Outcomes in Individuals with Diabetes Mellitus
Avitabile, N. A., Banka, A., & Fonseca, V. A. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.009 · Cited by 8
Self-citationBlonde, L., Baron, M. A., Zhou, R., & Banerji, M. A. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2766 · Cited by 6
Popp, M., Elhanafi, S. E., & Juan, Z. T. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0562-3 · Cited by 6
Trends in the Risk for Cardiovascular Disease among Adults with Diabetes in Oman
Al-Lawati, J. A., Morsi, M. M., Al‐Riyami, A., Mabry, R., Elsayed, M. K., El-Aty, M. A., & Lawati, H. J. A. (2015) · Sultan Qaboos University medical journal · doi:10.18295/2075-0528.1652 · Cited by 6
Kane, N. S. (2021) · Federal Practitioner · doi:10.12788/fp.0106 · Cited by 7
Glycemic Control and Mortality in Diabetic Patients Undergoing Hemodialysis: Much More to Learn
Bilous, R. W. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.005 · Cited by 6
Drug Therapies for the Primary Prevention of Cardiovascular Events: Trials and Errors
Psaty, B. M. (2010) · Circulation · doi:10.1161/circulationaha.109.933705 · Cited by 6
Are Diabetes Care Providers Too Glucocentric?
Lau, D. C. W. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.10.004 · Cited by 6
Saxon, D. R., Rasouli, N., & Eckel, R. H. (2018) · Drugs · doi:10.1007/s40265-017-0857-3 · Cited by 6
“A related systematic review that included 27,802 adults with T2DM evaluating the benefits and harms of intensive versus conventional glycemic control yielded similar results [9].”
BackgroundLau, B. T., Ismail, S. Z., Ng, S.-Y., & Mohmmad, N. (2018) · International Journal of Advancement in Life Sciences Research · doi:10.31632/ijalsr.2018v01i02.005 · Cited by 6
“Conversely, there was evidence showing no benefit for cardiovascular death and overall mortality outcomes with tight glycemic control (Kelly et al. 2009).”
BackgroundNicholas, S. B., & Tuttle, K. R. (2020) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2020.19.2.5 · Cited by 6
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Kapoor, K., George, P., & Miller, M. J. (2016) · Cardiology · doi:10.1159/000446471 · Cited by 5
Exploring the Relation Between Diabetes and HIV: A Narrative Review
Kumar, M., Singh, H., & Chakole, S. V. (2023) · Cureus · doi:10.7759/cureus.43909 · Cited by 5
Using individual patient data in meta-analyses of glucose-lowering studies
Yudkin, J. S., & Richter, B. (2009) · Diabetologia · doi:10.1007/s00125-009-1564-8 · Cited by 5
Passon, A. M., Drabik, A., & Sawicki, P. T. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.06.006 · Cited by 4
“Five [25,26,28,31,32] of 11 systematic reviews that included UKPDS 33 and 34 trials included the 411 participants and their associated events in the conventional treatment group of the metformin subtrial, although these participants were already included in the conventional treatment group of the main trial [59].”
BackgroundInfluentialAcute myocardial infarction associated to DPP-4 inhibitors.
Nunes, J. P. L., Rodrigues, J., & Melão, F. (2014) · PubMed Central · Cited by 4
Ensuring Patient Safety During the Transition to ESRD
Wagner, L.-A., & Fink, J. C. (2017) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2016.12.009 · Cited by 4
Crocodile blood supplementation protects vascular function in diabetic mice
Chook, C. Y. B., Chen, F. M., Tse, G., Leung, F. P., & Wong, W. T. (2021) · Food Production Processing and Nutrition · doi:10.1186/s43014-021-00066-w · Cited by 4
“…currently used therapeutic strategies for diabetic patients focus mainly on lowering blood glucose levels, diabetes medications only modestly improve cardiovascular disease outcomes, without significantly reducing cardiovascular mortality in diabetic patients (Kelly 2009; Turnbull et al. 2009).”
BackgroundTreatment of diabetic vasculopathy: an overview
Rahman, S., Majumder, & Rahman (2011) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s17512 · Cited by 4
Metformin Use Among Individuals at Risk for Type 2 Diabetes
Kuller, L. H. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0263-x · Cited by 4
Pacilli, A., Lamacchia, O., Fontana, A., Copetti, M., Cignarelli, M., Trischitta, V., & Cosmo, S. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124536 · Cited by 4
Validity of the Good Practice Guidelines: The example of type 2 diabetes
Tudrej, B. V., Favard, D., Vaillant-Roussel, H., Pouchain, D., Jaafari, N., & Boussageon, R. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108459 · Cited by 5
Badania typu CVOT (cardiovascular outcomes trials) w cukrzycy typu 2
Cypryk, K., & Małecki, P. (2018) · Endokrynologia Polska · doi:10.5603/ep.2018.0053 · Cited by 4
“In contrast, a meta-analysis of all four studies (UKPDS, ACCORD, ADVANCE, and VADT) for a five-year follow-up showed a statistically significant 15% (95% CI: 14–16%) reduction in non-fatal myocardial infarction and fatal myocardial infarction in patients using pharmacotherapy in the course of T2DM [9].”
Glicada para el diagnóstico de la diabetes, ¿un estándar universal?
de Torres, R. L. (2010) · Atención Primaria · doi:10.1016/j.aprim.2010.01.016 · Cited by 5
Tsujimoto, T., Sugiyama, T., Yamamoto‐Honda, R., Kishimoto, M., Noto, H., Morooka, M., Kubota, K., Kamimura, M., Hara, H., Kajio, H., et al. (2016) · Medicine · doi:10.1097/md.0000000000004307 · Cited by 4
“Intensive glycemic control did not prevent cardiovascular and overall mortality,([3]) necessitating the development of improved screening strategies for the early detection of cardiovascular complications.”
BackgroundGlycemia and cardiovascular diseases in type 2 diabetes
Skyler, J. S. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02276.x · Cited by 4
The enigma of glucose and cardiovascular disease
Desouza, C. V., Raghavan, V. A., & Fonseca, V. A. (2010) · Heart · doi:10.1136/hrt.2009.191866 · Cited by 4
“as a result of a lack of statistical power. To overcome this limitation, several meta-analyses of these trials have been carried out.”
BackgroundSelf-citationLovre, D., Htun, W., Carrion, C., & Fonseca, V. A. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0788-5 · Cited by 3
Self-citationVaccaro, O., Masulli, M., & Riccardi, G. (2018) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2018.04.008 · Cited by 3
Orozco‐Beltrán, D., Fernández, C. D. L. S., Gil-Guillén, V. F., Carratalá‐Munuera, C., & Pérez, J. N. (2010) · Atención Primaria · doi:10.1016/s0212-6567(10)70004-4 · Cited by 4
Norkus, A., Ostrauskas, R., Žalinkevičius, R., Radzevičienė, L., & Šulcaitė, R. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s45867 · Cited by 3
“Long-term maintenance of HbA 1c levels ,7% reduces the risk of complications from diabetes and progression to cardiovascular disease.(17,18) Treatment of diabetes, especially with insulin, is very individualized and should be determined by a physician with appropriate training and extensive clinical experience.”
Update on the Safety of Thiazolidinediones
Lieb, D. C., & McCall, A. L. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0099-1 · Cited by 3
“Diabetic patients have two to three times the risk for developing cardiovascular disease (CVD) compared to those without diabetes, and the proportion of CVD attributable to diabetes has increased over the past 50 years [2, 3]. Although the effects that lipid and blood pressure control have in preventing CVD in diabete…”
BackgroundVrints, C. J., Wood, D., Zamorano, J. L., Zannad, F. M., Karadeniz, Ş., Mezzani, A., Prescott, E., Ebrahim, S. B. J., Germanò, G., Hobbs, R. F., et al. (2013) · Cited by 3
Feldbauer, R., Heinzl, M. W., Klammer, C., Resl, M., Pohlhammer, J., Rosenberger, K., Almesberger, V., Obendorf, F., Schinagl, L., Wagner, T., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279308 · Cited by 3
Continuous glucose monitoring in high-risk individuals
Chen, Z., Zhang, Y., Sun, L., & Guo, W. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120733 · Cited by 2
Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., & Creager, M. A. (2014) · Cited by 2
Association of type 2 diabetes remission and risk of cardiovascular disease in pre‐defined subgroups
Hounkpatin, H. O., Stuart, B. L., Farmer, A. A., & Dambha‐Miller, H. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.280 · Cited by 4
Gliclazide MV: Proven Efficacy and Safety
Ivannikova, E. V., & Dudinskaya, Е. N. (2023) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2023-19-1-32-38 · Cited by 2
Poovieng, J., Jongcherdchootrakul, K., Srisawat, P., Mungthin, M., Rangsin, R., & Sakboonyarat, B. (2024) · Journal of Southeast Asian Medical Research · doi:10.55374/jseamed.v8.198 · Cited by 2
“(30, 31) A related study in Korea proved that smoking was associated with high TG. (32) Similarly, our study revealed that RTA personnel who had previously used tobacco and those who currently use tobacco had a 17% and 28% higher prevalence of high TG, respectively, compared to those who had never…”
ResultHaque, A., & Pant, A. B. (2025) · British journal of healthcare and medical research · doi:10.14738/bjhr.1203.19032 · Cited by 2
Fuentes, B., Amaro, S., de Leciñana, M. A., Arenillas, J. F., Martín, Ó. A., Castellanos, M., Freijo, M., García-Pastor, Gomis, M., Choco, M. G., et al. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2020.04.022 · Cited by 3
Azriel, S., Casal, F., Dalama, B., Varillas, F., Bajo, Á. V., Soto, A., & Barberá, G. (2014) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2014.06.004 · Cited by 2
Vivas, D., García-Rubira, J. C., Bernardo, E., Angiolillo, D. J., Martín, P., CALLE, A. L., Nuñez-Gil, I. J., Macaya, C., & Fernández‐Ortíz, A. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.05.020 · Cited by 2
Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk
Reboldi, G., Gentile, G., Angeli, F., Mazzotta, G., Martire, P., Garofoli, M., & Verdecchia, P. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0077-9 · Cited by 2
“Kelly et al. [ 34 ], combining data from nearly 28,000 participants in five large, randomized controlled trials (UKPDS 33, UKPDS 34, ACCORD, ADVANCE, and VADT) [19, 20, 22, 29, 31], documented that intensive glucose control provided beneficial effects on cardiovascular disease, particularly nonfatal myocardial i…”
BackgroundPerk, J., Backer, G. D., Gohlke, H., Graham, I. M., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cífková, R., et al. (2012) · Ghent University Academic Bibliography (Ghent University) · Cited by 2
Oxidative stress markers in diabetes
Butkowski, E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815776-3.00001-2 · Cited by 2
Друк, И. В., Snarskaya, D. I., & Goroshchenya, O. I. (2021) · Diabetes Mellitus · doi:10.14341/dm12469 · Cited by 2
Low HbA1c levels and mortality in type 2 diabetes mellitus
Ali, S., & Fonseca, V. A. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.69 · Cited by 2
Self-citationEfficacy and safety of shenqi compound for the treatment of diabetic macroangiopathy
Hu, Z., Yang, M., Xie, C., Gao, H., Fu, X., Xie, H., & Liu, Y. (2020) · Medicine · doi:10.1097/md.0000000000019682 · Cited by 2
Buehler, A. M. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2010.tde-10012011-104820 · Cited by 2
Clinical implications of the BARI 2D and COURAGE trials of coronary artery disease
Kuller, L. H. (2010) · Coronary Artery Disease · doi:10.1097/mca.0b013e32833bfdcd · Cited by 2
Insights From Monogenic Diabetes and Glycemic Treatment Goals for Common Types of Diabetes
Florez, J. C. (2014) · JAMA · doi:10.1001/jama.2013.283981 · Cited by 2
Coca, S. G., Ismail-Beigi, F., Haq, N., Krumholz, H. M., & Parikh, C. R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.2230 · Cited by 1
Koloi, A., Rydin, A. O., Milaneschi, Y., Lamers, F., Bosch, J. A., Pruin, E., van der Laan, S. W., Mishra, P. P., Lehtimäki, T. J., Kähönen, M. A. P., et al. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf038 · Cited by 1
“4,19 70 For example, a study by de Kluiver et al .”
Zhao, L., Ouyang, J., Song, Y., Qu, H., & Gao, Z. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70155 · Cited by 1
“Effective glycemic control can significantly reduce the incidence of diseases such as myocardial infarction [5, 6].”
Kocher, E. L., Uppal, T. S., Purohit, N., Sharma, H., Mohan, S., Sharma, R., Jarhyan, P., Ali, M., Ali, M. K., Tandon, N., et al. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14058-4 · Cited by 1
“Timely detection and appropriate treatment of hypertension and diabetes to achieve control targets can significantly decrease risk of cardiovascular events and other complications, reducing mortality and morbidity [2–4].”
Pharmacothérapie du diabète de type 2
Harper, W., CLEMENT, M. A., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R. R., Sherifali, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.006 · Cited by 1
Azriel, S., Casal, F., Dalama, B., Varillas, F., Bajo, Á. V., Soto, A., & Barberá, G. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2014.11.004 · Cited by 1
Guisasola, F. Á. (2010) · Atención Primaria · doi:10.1016/s0212-6567(10)70006-8 · Cited by 1
Glycemic Control in Type 2 Diabetes: The Tighter the Better?
Pham, S. V., Pham, P.-T. T., & CHILTON, R. J. (2013) · Clinical Diabetes · doi:10.2337/diaclin.31.1.25 · Cited by 1
Yen, V. (2016) · Springer eBooks · doi:10.1007/978-3-319-20797-1_53-1 · Cited by 1
Managing Chronic Coronary Artery Disease in Patients with Diabetes
Marx, N., & Reith, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00024-8 · Cited by 1
SGLT-2 Inhibitors: Drug Selection by Means of the System of Objectified Judgement Analysis Method
Janknegt, R., Reinders, M., & Bianchi, R. (2021) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2021.05.0750
Atherogenesis, coronary heart disease and insulin resistance syndrome in diabetes
Zafrir, B., & Plutzky, J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch70 · Cited by 1
CARDIAC DYSFUNCTION IN THE ZDF RAT: POSSIBLE MECHANISMS AND BENEFITS OF EXERCISE
VanHoose, L. (2011) · KU ScholarWorks (The University of Kansas) · Cited by 1
HbA1c: Is it the Most Important Therapeutic Target in outPatient Management of Diabetes?
Smith, S. A. (2011) · Wiley eBooks · doi:10.1002/9781444340280.ch11 · Cited by 1
Extent of glycemic control in type 2 diabetes mellitus: Close, but no cigar
Lerch, C., & Richter, B. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.08.009 · Cited by 1
Setting glycaemic targets in patients with type 2 diabetes. Where to now?
Distiller, L. A. (2009) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2009.10872208 · Cited by 1
Ideal Blood Glucose Control for Type 2 Diabetes Management: A New Clinical Equipoise
How, C. H. (2011) · Proceedings of Singapore Healthcare · doi:10.1177/201010581102000208 · Cited by 1
A translational viewpoint explaining its potential salutary effects
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw015 · Cited by 1
Improving the Prediction of Death from Cardiovascular Causes with Multiple Risk MarkersPreprint
Wang, X., Bakulski, K. M., Fansler, S. D., Mukherjee, B., & Park, S. K. (2023) · medRxiv · doi:10.1101/2023.01.21.23284863 · Cited by 1
“Associations between these blood biomarkers and CVD‐related morbidity and mortality risk have been examined over the last few decades.(24,27,28) Nevertheless, the predictive value of some of these commonly measured biomarkers has been examined only in a few studies.”
BackgroundDiabetes management by primary health care nurses in Auckland: A cross-sectional study
Daly, B. M. (2012) · ResearchSpace (University of Auckland) · Cited by 1
Chapitre 19 – Les complications chroniques du diabète
Wémeau, J.-L. (2014) · doi:10.1016/b978-2-294-71584-6.00019-2
Cardiovascular Disease in Diabetic Nephropathy
Hamm, L. L., Thethi, T. K., & Hering-Smith, K. S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_11
Self-citationAnalysing recent time trends in coronary heart disease and type 2 diabetes in the UK
Hardoon, S. L. (2012) · UCL Discovery (University College London)
The role of endoplasmic reticulum in human adipose tissue
Alhusaini, S. (2026) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33602866
Diabète de type 2: prise en charge efficace du risque vasculaire
Larger, É., Nobécourt, E., Rotariu, M., Radu, A., & Boîtard, C. (2009) · Sang thrombose vaisseaux · doi:10.1684/stv.2009.0413 · Cited by 1
Metadata
- Authors
- Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., & He, J.
- Affiliations
- Tulane University (US)
- Corresponding author
- Kelly, Tanika N.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2009-09-15
- Volume
- 151
- Issue
- 6
- Pages
- 394-403
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC3058557
- OpenAlex
- W2166180770
- Cited by
- 358
- References
- 43
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 7 · 2021: 18 · 2020: 16 · 2019: 10 · 2018: 16 · 2017: 16 · 2016: 21 · 2015: 28 · 2014: 29 · 2013: 29 · 2012: 40
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K08HL091108)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD043451)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, tight glycemic control, glycemic targets, cardiovascular disease, cardiovascular mortality, all-cause mortality, severe hypoglycemia, myocardial infarction, glycemic control
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Humans, Hypoglycemia, Hypoglycemic Agents, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
